{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705602",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705602_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  aceclofenac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705603",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705603_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  aliskiren  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705604",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705604_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  amiloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705605",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705605_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"azilsartan\" outputclass=\"int-drug\">azilsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  azilsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azilsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705606",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705606_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"bleomycin\" outputclass=\"int-drug\">bleomycin</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  bleomycin  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bleomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705607",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705607_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"candesartan\" outputclass=\"int-drug\">candesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  candesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Candesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705608",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705608_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  captopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705609",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705609_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  celecoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705610",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705610_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  ciclosporin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705611",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705611_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"cyclophosphamide\" outputclass=\"int-drug\">cyclophosphamide</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  cyclophosphamide  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclophosphamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705612",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705612_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">dalteparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  dalteparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705613",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705613_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"dexibuprofen\" outputclass=\"int-drug\">dexibuprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  dexibuprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705614",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705614_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  dexketoprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705615",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705615_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  diclofenac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705616",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705616_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"doxorubicin\" outputclass=\"int-drug\">doxorubicin</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  doxorubicin  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705617",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705617_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"drospirenone\" outputclass=\"int-drug\">drospirenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  drospirenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Drospirenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705618",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705618_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  enalapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705619",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705619_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">enoxaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  enoxaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705620",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705620_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  eplerenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705621",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705621_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"epoetin alfa\" outputclass=\"int-drug\">epoetin alfa</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  epoetin alfa  can increase the risk of thromboembolism. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705621_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"epoetin alfa\" outputclass=\"int-drug\">epoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  darbepoetin alfa  and  epoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705622",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705622_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"epoetin beta\" outputclass=\"int-drug\">epoetin beta</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  epoetin beta  can increase the risk of thromboembolism. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705622_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"epoetin beta\" outputclass=\"int-drug\">epoetin beta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  darbepoetin alfa  and  epoetin beta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705623",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705623_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"epoetin zeta\" outputclass=\"int-drug\">epoetin zeta</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  epoetin zeta  can increase the risk of thromboembolism. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705623_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"epoetin zeta\" outputclass=\"int-drug\">epoetin zeta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  darbepoetin alfa  and  epoetin zeta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin zeta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705624",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705624_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"eprosartan\" outputclass=\"int-drug\">eprosartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  eprosartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eprosartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705625",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705625_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  etodolac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705626",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705626_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  etoricoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705627",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705627_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"fluorouracil\" outputclass=\"int-drug\">fluorouracil</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  fluorouracil  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluorouracil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705628",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705628_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  flurbiprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705629",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705629_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"fulvestrant\" outputclass=\"int-drug\">fulvestrant</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  fulvestrant  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fulvestrant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705630",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705630_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"heparin (unfractionated)\" outputclass=\"int-drug\">heparin (unfractionated)</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  heparin (unfractionated)  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin (unfractionated)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705631",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705631_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  ibuprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705632",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705632_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  imidapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705633",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705633_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  indometacin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705634",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705634_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"irbesartan\" outputclass=\"int-drug\">irbesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  irbesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irbesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705635",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705635_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  ketoprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705636",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705636_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  ketorolac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705637",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705637_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"lenalidomide\" outputclass=\"int-drug\">lenalidomide</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  lenalidomide  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705638",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705638_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  lisinopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705639",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705639_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"losartan\" outputclass=\"int-drug\">losartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  losartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Losartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705640",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705640_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  mefenamic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705641",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705641_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  meloxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705642",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705642_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  methotrexate  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705643",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705643_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"mitomycin\" outputclass=\"int-drug\">mitomycin</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  mitomycin  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705644",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705644_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  nabumetone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705645",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705645_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  naproxen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705646",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705646_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"olmesartan\" outputclass=\"int-drug\">olmesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  olmesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olmesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705647",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705647_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  parecoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705648",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705648_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"pentostatin\" outputclass=\"int-drug\">pentostatin</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  pentostatin  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentostatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705649",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705649_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  perindopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705650",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705650_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  piroxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705651",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705651_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"pomalidomide\" outputclass=\"int-drug\">pomalidomide</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  pomalidomide  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pomalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705652",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705652_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"potassium aminobenzoate\" outputclass=\"int-drug\">potassium aminobenzoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  potassium aminobenzoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium aminobenzoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705653",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705653_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"potassium canrenoate\" outputclass=\"int-drug\">potassium canrenoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  potassium canrenoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium canrenoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705654",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705654_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"potassium chloride\" outputclass=\"int-drug\">potassium chloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  potassium chloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705655",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705655_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  quinapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705656",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705656_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"raloxifene\" outputclass=\"int-drug\">raloxifene</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  raloxifene  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Raloxifene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705657",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705657_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  ramipril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705658",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705658_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  spironolactone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705659",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705659_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  sulindac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705660",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705660_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  tacrolimus  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tacrolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705661",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705661_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"tamoxifen\" outputclass=\"int-drug\">tamoxifen</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  tamoxifen  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tamoxifen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705662",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705662_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"telmisartan\" outputclass=\"int-drug\">telmisartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  telmisartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telmisartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705663",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705663_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  tenoxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705664",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705664_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  thalidomide  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705665",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705665_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  tiaprofenic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705666",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705666_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"tibolone\" outputclass=\"int-drug\">tibolone</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  tibolone  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tibolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705667",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705667_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">tinzaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  tinzaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705668",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705668_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  tolfenamic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705669",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705669_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"tolvaptan\" outputclass=\"int-drug\">tolvaptan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  tolvaptan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolvaptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705670",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705670_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"toremifene\" outputclass=\"int-drug\">toremifene</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  toremifene  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Toremifene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705671",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705671_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  trandolapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705672",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705672_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"tranexamic acid\" outputclass=\"int-drug\">tranexamic acid</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  tranexamic acid  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranexamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705673",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705673_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"tretinoin\" outputclass=\"int-drug\">tretinoin</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  tretinoin  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tretinoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705674",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705674_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  triamterene  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705675",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705675_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  trimethoprim  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimethoprim</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705676",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705676_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"valsartan\" outputclass=\"int-drug\">valsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  valsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705677",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705677_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  vinblastine  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinblastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705678",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705678_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  vincristine  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vincristine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705679",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705679_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  vindesine  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vindesine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705680",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705680_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  vinflunine  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705681",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2#bnf_i1557280705681_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-heading-drug\">darbepoetin alfa</ph> and <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  darbepoetin alfa  and  vinorelbine  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinorelbine</title>"
					}
				}
			],
			"hasSearchLabel": " Darbepoetin alfa  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/darbepoetin-alfa-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Darbepoetin alfa </title>"
			},
			"rdfs:label": "darbepoetin alfa"
		}
	]
}